EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway

Shan Lin, Bangwei Wu, Shengjia Sun, Tao Sun

International Journal of Molecular Sciences · 02.03.2026 · 27 (5) · 2341

DOI: 10.3390/ijms27052341 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.03.2026. Verfasst von Shan Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Huashan Hospital Affiliated to Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China. Hauptthemen laut MEDLINE: Diabetic Cardiomyopathies, Antibodies, Monoclonal, Humanized, PCSK9 Inhibitors, p38 Mitogen-Activated Protein Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PCSK9 is a gene associated with familial hypercholesterolemia and is involved in other biological processes such as apoptosis, autophagy, and inflammatory responses. This study aims to further validate whether PCSK9 inhibitors can improve diabetic cardiomyopathy and elucidate their mechanisms of action. This study utilized H9c2 cells and C57BL/6J mice to validate the efficacy of the PCSK9 inhibitor alirocumab through in vivo and in vitro experiments. In vitro, alirocumab was shown to enhance cell viability and reduce oxidative stress in H9c2 cells under high glucose stress. It can also decrease the expression levels of inflammatory reaction and mitochondrial apoptosis-related proteins. Through in vivo experiments, we demonstrated that alirocumab can reduce myocardial hypertrophy and improve cardiac function in diabetic cardiomyopathy mice. Meanwhile, alirocumab treatment increased mitochondrial size and quantity in the hearts of diabetic cardiomyopathy mice, promoted mitochondrial fusion, and reduced the number of damaged mitochondria. Alirocumab could also reduce the percentage of myocardial fibrosis and oxidative stress in mice. Finally, we found that alirocumab can improve cardiac function in diabetic cardiomyopathy through the ERK/p38 MAPK pathway. Our data demonstrate that the PCSK9 inhibitor alirocumab provides protective effects against diabetic cardiomyopathy, offering fundamental experimental support for its clinical application in this condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic CardiomyopathiesAntibodies, Monoclonal, HumanizedPCSK9 Inhibitorsp38 Mitogen-Activated Protein KinasesMAP Kinase Signaling SystemAnimalsMiceOxidative StressMice, Inbred C57BLProprotein Convertase 9MaleCell LineRatsMyocytes, CardiacDiabetes Mellitus, Experimental

Stichwörter der Autor:innen

MAPK signaling pathwayPCSK9 inhibitordiabetic cardiomyopathy

Substanzen

alirocumabAntibodies, Monoclonal, HumanizedPCSK9 Inhibitorsp38 Mitogen-Activated Protein KinasesProprotein Convertase 9Pcsk9 protein, mouse

Autor:innen und Institutionen

  • Department of Cardiology, Huashan Hospital Affiliated to Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China.

Zitieren

APA

Lin, S., Wu, B., Sun, S., & Sun, T. (2026). PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. International Journal of Molecular Sciences, 27(5), 2341. https://doi.org/10.3390/ijms27052341

Vancouver

Lin S, Wu B, Sun S, Sun T. PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. International Journal of Molecular Sciences. 2026;27(5):2341. doi:10.3390/ijms27052341

BibTeX
@article{Lin2026,
  author = {Lin, Shan and Wu, Bangwei and Sun, Shengjia and Sun, Tao},
  title = {PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {5},
  pages = {2341},
  doi = {10.3390/ijms27052341}
}
Kostenlos starten →